Posatex Dailymed
Prescription Animal - Corticosteroid
- Merck Sharp & Dohme Corp.
Generic: orbifloxacin, mometasone furoate, and posaconazole is used for the treatment of Dermatomycoses Facial Dermatoses Foot Dermatoses Hand Dermatoses Herpes Simplex Herpes Zoster Inflammation Leg Dermatoses Pruritus Rhinitis, Allergic, Perennial Scalp Dermatoses Tuberculosis, Cutaneous Aspergillosis Candidiasis Candidiasis, Oral Hypersensitivity
Go PRO for all pill images
Antibacterial, anti-inflammatory, antifungal
For Otic Use in Dogs Only
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Federal law prohibits the extralabel use of this drug in food-producing animals.
Description Section
DESCRIPTION: Each gram of POSATEX® Otic Suspension contains 10 mg of orbifloxacin; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 1 mg of posaconazole in a mineral oil based system containing a plasticized hydrocarbon gel.
Four drops of POSATEX® Otic Suspension delivers approximately 1.0 mg orbifloxacin, 0.1 mg of mometasone furoate monohydrate, and 0.1 mg of posaconazole.
Veterinary Indications Section
INDICATIONS: POSATEX® Otic Suspension is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).
Dosage & Administration Section
DOSAGE AND ADMINISTRATION: Shake well before use. For dogs weighing less than 30 lbs. instill 4 drops of POSATEX® Otic Suspension once daily into the ear canal. For dogs weighing 30 lbs. or more, instill 8 drops once daily into the ear canal. Therapy should continue for 7 consecutive days.
Contraindications Section
CONTRAINDICATIONS: POSATEX® Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to quinolones, mometasone furoate monohydrate, or posaconazole. Do not use in dogs with known tympanic perforation (see PRECAUTIONS ).
Warnings:
Human Warnings: Not for use in humans. Keep out of reach of children.
Animal Warnings: Do not administer orally. Immediately discontinue use of POSATEX® Otic Suspension if hearing loss is observed during treatment (see ADVERSE REACTIONS ).
Precautions Section
PRECAUTIONS: The use of POSATEX® Otic Suspension in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membranes should be confirmed before administering this product.
Avoid prolonged or repeated use of POSATEX® Otic Suspension. Long-term use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see ANIMAL SAFETY ).
The safe use of POSATEX® Otic Suspension in dogs used for breeding purposes, during pregnancy or in lactating bitches, has not been evaluated. The systemic administration of quinolones has been shown to produce cartilage erosions of weight bearing joints and other signs of arthropathy in immature animals of various species.
Adverse Reactions Section
ADVERSE REACTIONS: In the field study, 143 dogs were treated with POSATEX® Otic Suspension. Of those, 1 dog with bilateral otitis externa developed hearing loss. POSATEX® Otic Suspension treatment was discontinued and the condition resolved after one week.
To report suspected adverse reactions, call 1-800-224-5318.
For a copy of the Material Safety Data Sheet (MSDS) call 1-800-770-8878.
Clinical Pharmacology:
Orbifloxacin: Orbifloxacin is a synthetic fluoroquinolone antibacterial agent. The bactericidal action of fluoroquinolones is concentration-dependent and results from interference with bacterial DNA gyrase and topoisomerase IV. Since these enzymes are needed for bacterial DNA synthesis and transcription, fluoroquinolones disrupt bacterial replication and lead to bacterial cell death.
Mometasone: Mometasone furoate monohydrate is a topical corticosteroid characterized by a (2') furoate 17-ester having chlorine at the 9 and 21 positions.
Posaconazole: Posaconazole is a broad-spectrum triazole antifungal agent. The mechanism by which triazoles exert fungicidal action involves the selective inhibition of the enzyme lanosterol a C14 demethylase (a microsomal cytochrome P-450- dependent enzyme) involved in ergosterol biosynthesis in yeasts and filamentous fungi.
Systemic absorption of the active ingredients was determined in single-dose radiolabelled studies with 14C-orbifloxacin, 3H-mometasone furoate, and 14C-posaconazole contained within the POSATEX® Otic Suspension formulation and placed into the ear canals of normal beagle dogs. Most of the absorption occurred in the first few days after administration. The extent of percutaneous absorption of topical medications is influenced by many factors including the integrity of the epidermal barrier. Inflammation can increase the percutaneous absorption of drugs.
EFFECTIVENESS: The effectiveness of POSATEX® Otic Suspension was evaluated in a placebo-controlled, double-blind, multi-site field study. One hundred and ninety one dogs with naturally occurring clinical otitis externa associated with both yeast and bacteria were randomly allocated to either POSATEX® Otic Suspension or placebo ointment. Of the 160 dogs evaluated for effectiveness, 122 were treated with POSATEX® Otic Suspension and 38 were treated with placebo ointment. Treatments were administered once daily for 7 consecutive days. Assessment of effectiveness was based on improvement in clinical signs at re-evaluation 2-7 days following administration of the last dose.
Compared to the placebo, a significant percent of dogs treated with POSATEX® Otic Suspension showed improvement in clinical signs (discomfort, erythema, and swelling) caused by otitis externa associated with one or more of the following organisms: Malassezia pachydermatis, coagulase positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis.
Percent of Dogs Showing Improvement in Clinical Signs of Otitis Externa Clinical Sign POSATEX® Otic Suspension Group Placebo Group Significance Discomfort 88% 45% p<0.0001 External Ear Canal Erythema 81% 39% p<0.0001 External Ear Canal Swelling 83% 49% p=0.0001
Animal Pharmacology & Or Toxicology Section
ANIMAL SAFETY: POSATEX® Otic Suspension was administered at 1,3, and 5 times the recommended dosage for 21 consecutive days. The control group received the vehicle in both ears at the clinical dose given five times per day. There was a slight decrease in serum cortisol concentration after ACTH stimulation on Day 21 in the 5× group. Erythema was noted in all groups. Aural pain, swelling, or heat were each noted in 3 separate dogs in the 5× group.
Storage And Handling Section
STORAGE INFORMATION: Store at temperatures between 2°-30°C (35.6°-86°F).
Shake well before use.
How Supplied Section
HOW SUPPLIED: POSATEX® Otic Suspension is available in 7.5 g, 15 g, and 30 g plastic bottles.
Approved by FDA under NADA # 141-266Copyright© 2009, 2019 Intervet Inc., a subsidiary of Merck & Co. Inc.Madison, NJ 07940 USAAll rights reserved.Made in GermanyRev. 02/2019
Principal Display Panel - 30 G Bottle Label
Posatex® Otic Suspension(orbifloxacin, mometasonefuroate monohydrate andposaconazole suspension)
Antibacterial,Anti-inflammatory,Antifungal
Caution: Federal lawrestricts this drug to use byor on the order of a licensedveterinarian.
Federal law prohibits theextralabel use of this drugin food-producing animals.
KEEP OUT OF REACHOF CHILDREN.
Approved by FDA under NADA # 141-266NDC 0061-0089-03
30g
MERCKAnimal Health
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
